Información de la revista
Vol. 26. Núm. 4.
Páginas 270-274 (enero 2003)
Vol. 26. Núm. 4.
Páginas 270-274 (enero 2003)
Acceso a texto completo
Tratamiento del síndrome hepatorrenal
Visitas
17537
M. Guevara
Autor para correspondencia
mguevara@clinic.ub.es
Correspondencia: Dra. M. Guevara. Unidad de Hepatología. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España.
Correspondencia: Dra. M. Guevara. Unidad de Hepatología. Hospital Clínic. Villarroel, 170. 08036 Barcelona. España.
Unidad de Hepatología. Hospital Clínic. Barcelona. España
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
V. Arroyo, P. Ginés, A. Gerbes, F.J. Dudley, P. Gentilini, G. Laffi, et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
Hepatology, 23 (1996), pp. 164-176
[2.]
M.H. Koppel, J.N. Coburn, M.M. Mims, H. Goldtein, H. Boyle, M.E. Rubini.
Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease.
N Engl J Med, 280 (1969), pp. 1367-1371
[3.]
S. Iwatsuki, M.M. Popovtzer, J.L. Corman, M. Ishikawa, C.W. Putnam, F.H. Katz, et al.
Recovery from hepatorenal syndrome after orthotopic liver transplantation.
N Engl J Med, 289 (1973), pp. 1155-1159
[4.]
R.W. Schrier, V. Arroyo, M. Bernardi, M. Epstein, J.H. Henriksen, J. Rodés.
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology, 8 (1988), pp. 1151-1157
[5.]
A. Ginès, A. Escorsell, P. Ginès, G. Fernández-Esparrach, J. Salo, W. Jiménez, et al.
Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites.
Gastroenterology, 105 (1993), pp. 229-236
[6.]
M. Guevara, P. Gines, G. Fernández-Esparrach, P. Sort, J.M. Salmeron, W. Jiménez, et al.
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Hepatology, 27 (1998), pp. 35-41
[7.]
V. Gülberg, M. Bilzer, A.L. Gerbes.
Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Hepatology, 30 (1999), pp. 870-875
[8.]
O. Le Moine, A. el Nawar, R. Jagodzinski, N. Bourgeois, M. Adler, M. Gelin, et al.
Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome.
Acta Gastroenterol Belg, 61 (1998), pp. 268-270
[9.]
N. Ganne-Carrie, A. Hadengue, P. Mathurin, F. Durand, S. Erlinger, J.P. Benhamou.
Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Dig Dis Sci, 41 (1996), pp. 1054-1056
[10.]
J. Uriz, P. Ginés, A. Cardenas, P. Sort, W. Jiménez, J.M. Salmerón, et al.
Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome.
J Hepatol, 33 (2000), pp. 43-48
[11.]
J.P. Mulkay, H. Louis, V. Donckter, N. Bourgeois, M. Adler, J. Deviere, et al.
Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
Acta Gastroenterol Belg, 64 (2001), pp. 15-19
[12.]
R. Ortega, P. Ginès, J. Uriz, A. Cardenas, B. Calahorra, D. de las Heras, et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study.
Hepatology, 36 (2002), pp. 941-948
[13.]
R. Moreau, F. Durand, T. Poynard, C. Duhamel, J.P. Cervoni, P. Ichai, et al.
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a restrospective multicenter study.
Gastroenterology, 50 (2002), pp. 90-94
[14.]
P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Romero, R. Merenda, et al.
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Hepatology, 29 (1999), pp. 1690-1697
[15.]
C. Duvoux, D. Zanditenas, C. Hezode, A. Chauvat, J. Metreau.
Noradrenalin for treatment of type 1 hepatorenal syndrome (HRS).
J Hepatol, 34 (2001), pp. 103A
[16.]
M. Guevara, P. Ginés, J.C. Bandi, R. Gilabert, P. Sort, W. Jiménez, et al.
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
Hepatology, 28 (1998), pp. 416-422
[17.]
K.A. Brensing, J. Textro, J. Perz, P. Schiedermaier, P. Raab, H. Strunk, et al.
Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-trasplant patients with hepatorenal syndro-me: a phase II study.
Gut, 47 (2000), pp. 288-295
[18.]
A. Ochs, M. Rössle, K. Haag, A. Gerbes, A. Morgenroth, P. Deibert, et al.
TIPS for hepatorenal syndrome.
Hepatology, 20 (1994), pp. 114A
[19.]
I. Alam, N.M. Bass, J.M. LaBerge, E. Ring, K.A. Somberg.
Treatment of hepatorenal syndrome with the transjugular intrahepatic shunt (TIPS).
Gastroenterology, 108 (1995), pp. A1024
[20.]
P. Ginès, J. Uriz, B. Calahorra, G. García-Tsao, P.S. Kamath, L.R. Del Árbol, et al.
Transjugular intrahepatic portosystemic shunting versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis.
A multicenter randomised comparative study Gastroenterology, 123 (2002), pp. 1839-1847
[21.]
S.L. Linas, J.W. Shaffer, E.E. Moore, J.T. Good Jr, R. Giansiracusa.
Peritoneovenous shunt in the management of the hepatorenal syndrome.
Kidney Int, 30 (1986), pp. 736-740
[22.]
P. Ginés, V. Arroyo, V. Vargas, R. Planas, F. Casafont, J. Panés, et al.
Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites.
N Engl J Med, 325 (1991), pp. 829-835
[23.]
G.O. Pérez, T.A. Golper, M. Epstein, J.R. Oster.
Dyalisis hemofiltration, and other extracorporeal techniques in the treatment of renal complications of liver disease.
The Kidney in liver disease, 4th ed, pp. 517-528
[24.]
S.R. Mitzner, J. Stange, S. Klammt, T. Risler, C.M. Erley, B.D. Bader, et al.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized controlled clinical trial.
Liver Transpl, 6 (2000), pp. 277-286
[25.]
T.A. Gonwa, C.A. Morris, R.M. Goldstein, B.S. Husbert, G.B. Klintmalm.
Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndromeexperience in 300 patients.
Transplantation, 91 (1991), pp. 428-430
[26.]
M. Navasa, F. Feu, J.C. García-Pagan, W. Jiménez, J. Llach, A. Rimola, et al.
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis.
Hepatology, 17 (1993), pp. 355-360
[27.]
P. Ginés, L. Tito, V. Arroyo, R. Planas, J. Panes, J. Viver, et al.
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
Gastroenterology, 94 (1988), pp. 1493-1502
[28.]
P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, L. Ruiz del Árbol, et al.
Effect of plasma volume expansion on renal impaiment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med, 341 (1999), pp. 403-409
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados